Item 3.

Legal Proceedings

68

 Item 4.

Mine Safety Disclosures

68

PART II

 Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

69

 Item 6.

Reserved

70

 Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

71

 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

81

 Item 8.

Financial Statements and Supplementary Data

82

 Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

82

 Item 9A.

Controls and Procedures

82

 Item 9B.

Other Information

84

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

85

PART III

 Item 10.

Directors, Executive Officers and Corporate Governance

86

 Item 11.

Executive Compensation

86

 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

86

 Item 13.

Certain Relationships and Related Transactions, and Director Independence

86

 Item 14.

Principal Accountant Fees and Services

86

PART IV

 Item 15.

Exhibits and Financial Statement Schedules

87

 Item 16.

Form 10-K Summary

93

SIGNATURES

94

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical fact contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "aim", “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words, or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•
our commercialization, marketing, and manufacturing capabilities and strategy;

•
our expectations regarding the timing of clinical study commencements and reporting results from same; 

•
the timing and likelihood of regulatory approvals for, or commercialization of, our product candidates;

•
the anticipated indications for our product candidates, if approved; 

•
the potential market opportunities for commercializing our products and product candidates; 

•
our expectations regarding the potential market size and the size of the patient populations for our products and product candidates, if approved for commercial use; 

•
estimates of our expenses, revenue, capital requirements, and our needs for additional financing; 

•
our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical studies; 

•
the implementation of our business model and strategic plans for our business, products and product candidates and the integration and performance of any businesses we have acquired or may acquire;

•
the initiation, timing, progress, and results of ongoing and future preclinical and clinical studies, and our research and development programs; 

•
the scope of protection we are able to establish and maintain for intellectual property rights covering our products and product candidates; 

•
our ability to maintain and establish collaborations or strategic relationships or obtain additional funding; 

•
our ability to maintain and establish relationships with third parties, such as contract research organizations, contract manufacturing organizations, suppliers, and distributors;

•
our financial performance, including our expectations for profitability for 2027, and the expansion of our organization; 

•
our ability to obtain supply of our products and product candidates;

•
the scalability and commercial viability of our manufacturing methods and processes;

•
developments and projections relating to our competitors and our industry;

•
stagnating or worsening business and economic conditions and increasing geopolitical instability, including inflationary pressures, general economic slowdown or a recession, high interest rates, foreign exchange rate volatility, financial institution instability, and changes in monetary policy;

•
the impact of market conditions and volatility on unrealized gains or losses on our nonqualified deferred compensation plan investments and our financial results; and

•
other risks and uncertainties, including those listed under “Part I,